Weill Cornell Medical College, New York, New York.
Weill Cornell Medical College, New York, New York.
Clin Gastroenterol Hepatol. 2022 Jun;20(6):e1493-e1499. doi: 10.1016/j.cgh.2021.12.007. Epub 2021 Dec 9.
Immunization against the spike protein of SARS-CoV-2 reduces transmission and severe outcomes. However, little is known regarding the impact of immune-mediated diseases and immunosuppressive medications on the efficacy of vaccination. Vaccination immunity is transient, with breakthrough cases increasing at longer time intervals since the last dose. Although there are data on SARS-CoV-2 vaccine on early seroconversion in patients with inflammatory bowel disease (IBD), no data in the same cohort exist describing the durability of these antibodies over time. We sought to investigate the impact of IBD and its therapies on postvaccination antibody response and kinetics of immunogenicity decline, because these findings may better inform clinical guidelines and recommendations on precautions and booster vaccination.
接种 SARS-CoV-2 的刺突蛋白可降低传播和严重后果。然而，对于免疫介导性疾病和免疫抑制药物对疫苗接种效果的影响知之甚少。接种疫苗后的免疫力是短暂的，自上次接种以来，随着时间的推移，突破性病例的数量不断增加。虽然有关于炎症性肠病（IBD）患者 SARS-CoV-2 疫苗早期血清转化的数据，但在同一队列中，尚无关于这些抗体随时间推移的持久性的数据。我们旨在研究 IBD 及其治疗方法对疫苗接种后抗体反应和免疫原性下降动力学的影响，因为这些发现可能更好地为临床指南和关于预防措施和加强疫苗接种的建议提供信息。
